Efficacy and safety of dapagliflozin and acarbose in type 1 diabetes mellitus

Authors
Category Primary study
Registry of TrialsChinese Clinical Trial Register
Year 2018
INTERVENTION: Group 2:dapagliflozin 10mg qd;Group 1:Acarbose 50mg tid; CONDITION: Type 1 diabetes mellitus PRIMARY OUTCOME: mean amplitude of glycemic excursions; INCLUSION CRITERIA: Diagnosed type 1 diabetes, age 18‐60 years old, using insulin to control blood glucose
Epistemonikos ID: 4adab34d0ff6661147ac6e19e77c9adf488303fd
First added on: Jul 02, 2024